Search
for
Sort by
Research 30 of 1000+
- Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases
- Crystal Structure and Synthesis of 17.ALPHA.-Acetoxy-6,7-epoxypregn-4-ene-3,20-dione
- Crystal Structure and Synthesis of 17α-Acetoxy-4-bromopregn-4-ene-3,20-dione
- Crystal Structure and Synthesis of 17α-Acetoxy-pregn-4,6-diene-3,20-dione
- Androgenic and anti-androgenic effects of progesterone derivatives with different halogens as substituents at the C-6 position
- Molecular Interactions of New Pregnenedione Derivatives
- Androgen Receptor Antagonists (Antiandrogens) Structure-Activity Relationships
- New Progesterone Esters as 5.ALPHA.-Reductase Inhibitors.
- Recent discoveries and developments of androgen receptor based therapy for prostate cancer
- Synthesis and Study of Some 17a-aza-D-homo Steroids as 5α-Reductase Inhibitors
- Effects of 17-β-Estradiol and ICI 182 780 on Hair Growth in Various Strains of Mice
- Review of the effects of 17α-estradiol in humans: a less feminizing estrogen with neuroprotective potential
- The diagnosis of nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, based on serum basal or post-ACTH stimulation 17-hydroxyprogesterone, can lead to false-positive diagnosis
- Compatibility of 17-a-estradiol, Caffeine, Clobetasol Propionate, Finasteride Melatonin, Metronidazole, Spironolactone, Tretinoin, and Triamcinolone in Trichosol, a Natural Vehicle for Hair Solutions.
- Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment
- Targeting lymphoid-derived IL-17 signaling to delay skin aging
- Alopecia Diffusa while Using Interleukin-17 Inhibitors against Psoriasis Vulgaris
- p53 Is a Direct Transcriptional Repressor of Keratin 17: Lessons from a Rat Model of Radiation Dermatitis
- <i>Trichophyton tonsurans</i>‐induced kerion celsi with decreased defensin expression and paradoxically increased interleukin‐17A production
- Biological Profile of Cortexolone 17a-Propionate (CB-03-01), a New Topical and Peripherally Selective Androgen Antagonist
- A summary of in vitro, phase I, and phase II studies evaluating the mechanism of action, safety, and efficacy of clascoterone (cortexolone 17a propionate, CB-03-01) in androgenetic alopecia
- Increased expression of psoriasin (S100A7) and interleukin 17 (IL-17) in lesional skin in lichen planopilaris
- IL-17a induces age-related olfactory dysfunction by impairing regeneration and promoting respiratory metaplasia in mice
- Association of Serum IL-17A and IL-23 Levels With Alopecia Areata: A Cross-Sectional Comparative Study
- Assessment of Interleukin-17A and Interleukin-2 Serum Levels in Patients with Alopecia Areata
- Increased serum interleukin-17A levels correlate with disease severity and poor prognostic factors in patients with alopecia areata
- DEVELOPING AND VALIDATING AN HPLC METHOD TO QUANTIFY SIMULTANEOUSLY DUTASTERIDE AND THEIR RELATED MOLECULES (DUTASTERIDE ACID, 2,5 BIS- (TRI FLUORO METHYL)-ANILINE AND DUTASTERIDE 17 α-EPIMER) IN CAPSULES
- Cortexolone 17a-propionate: A new antiandrogen acting on hair dermal papilla cells for the treatment of androgenic alopecia
- Cortexolone 17a-propionate: Preclinical profile of a new topical, skin selective, steroidal antiandrogen
- Regularities of Change Concentrations of Interleukin-17A, Interleukin-2 and Interleukin-10 in the Blood of People with Alopecia Areata before and after Treatment with Platelet-Rich Plasma